期刊
CURRENT OPINION IN IMMUNOLOGY
卷 54, 期 -, 页码 86-92出版社
CURRENT BIOLOGY LTD
DOI: 10.1016/j.coi.2018.05.015
关键词
-
类别
资金
- Fondation Acteria
- Swiss National Science Foundation Ambizione grant [PZ00P3_148185]
- Research Fund of the Swiss Lung Association, Berne
- Uniscientia foundationa
- Swiss National Science Foundation (SNF) [PZ00P3_148185] Funding Source: Swiss National Science Foundation (SNF)
lmmunoglobulin E (IgE) represents the least abundant antibody isotype in human serum. Nevertheless, it has the ability to induce potent allergic reactions. As a key component in the development and manifestation of hypersensitivity responses against usually non-hazardous foreign substances, IgE has become a major target of investigation and the subject of multiple therapeutic approaches for the treatment of allergies. Recent advances in the understanding of pathophysiologic mechanisms underlying IgE-associated allergic disorders have led to the generation of new drug candidates that are currently in development or under clinical evaluation. In this review, we highlight molecular and structural mechanisms underlying the different anti-IgE molecules and suggest a concept of multilevel targeting using a new class of disruptive IgE inhibitors to potentially optimize treatment efficacy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据